Video

Peter Chin, MD

Publish date: July 18, 2016

Dr. Chin discusses the results of several studies presented at the 2016 Annual Meeting of the CMSC that relate to ocrelizumab.


 

References

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Oral contraceptive efficacy unaffected by dimethyl fumarate
MDedge Neurology
Real-world data favor dimethyl fumarate, fingolimod for MS
MDedge Neurology
Exercise improves sleep and may improve cognitive/physical function in MS
MDedge Neurology
Alemtuzumab beneficial for MS patients of African descent
MDedge Neurology
Real-world MS relapse rate is low for dimethyl fumarate
MDedge Neurology
Frederick Munschauer, MD
MDedge Neurology
Choosing MS Treatments From the Therapeutic Armamentarium
MDedge Neurology
Ocrelizumab May Be More Effective for Relapsing-Remitting MS Than Interferon
MDedge Neurology
Can Stem Cells Halt Progression of MS?
MDedge Neurology
Siponimod shows promise through 24 months in relapsing-remitting MS
MDedge Neurology